ArticleClinical hypertension2025
Korea Hypertension Fact Sheet 2024: nationwide population-based analysis with a focus on young adults.
Article in Clinical hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2026Trial
- Low-Dose Telmisartan/Amlodipine in Essential Hypertension: A Phase III Trial.Journal of clinical hypertension (Greenwich, Conn.) · 2026Trial
- Low-Dose TEL/AML/CHTD SPC Versus Standard-Dose TEL in Hypertension: Phase III RCT.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Efficacy and Safety of Telmisartan 20 mg/S-Amlodipine 2.5 mg versus Telmisartan 40 mg in Patients with Hypertension, Inadequately Controlled on Telmisartan 20 mg Monotherapy: A Randomized, Double-Blind, Multicenter, Phase 3 Trial.Drug design, development and therapy · 2026Trial
- A Molecular Diagnostic Approach for Hypertension Through Establishment of a Metabolite Risk Score Using a Multi-Metabolite Panel Identified via UHPLC-MS/MS.International journal of molecular sciences · 2026Article
- Latent profiles of body composition in older adults with hypertension: associations with physical fitness and differences in blood pressure and fasting plasma glucose.Physical activity and nutrition · 2026Article
- Temporal Trends in the Distribution of Extracranial Carotid and Intracranial Artery Disease Among South Korean Stroke Patients.Journal of stroke · 2026Article
- Association between cumulative biological risk and hypertension in older adults in Korea: a population-based cross-sectional study.Journal of Korean biological nursing science · 2026Article
- Socioeconomic gradients in hypertension prevalence and management: a cross-sectional study.BMC public health · 2026Article
- Hypertension Education, Provider, and Cardio-Cerebrovascular Symptom Awareness: 2024 Korea Community Health Survey.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Degree of urbanization and the prevalence of hypertension and diabetes mellitus in South Korea (Insight from Gyeonggi Province): A cross-sectional analysis with temporal trends, 2008-2023.BMC public health · 2026Article
- Determinants of Self-Reported Unmet Healthcare Needs by Disability Status: A Secondary Cross-Sectional Analysis of Linked National Survey and Administrative Data from Korea.Healthcare (Basel, Switzerland) · 2026Article
- Single-Pill Combination Olmesartan/Amlodipine/Hydrochlorothiazide Safety and Effectiveness in Older Patients with Hypertension: Pooled Analysis of Post-Approval Observational Studies.Advances in therapy · 2026Article
- Association Between Remnant Cholesterol and Muscle Mass and Quality: Insights from Muscle Quality Mapping and Abdominal Computed Tomography.Diagnostics (Basel, Switzerland) · 2026Article
- Trends of new diagnosis and treatment initiation of hypertension during the COVID-19 pandemic in Korea.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- The MASLD Journey in the General Population: Linkage-to-Care and Patient-Reported Uptake of Fibrosis Risk Assessment.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Efficacy and safety of metabolic bariatric surgery in patients aged ≥55 years: a multicenter retrospective cohort study in East Asians.Annals of surgical treatment and research · 2026Article
- Proteomic Risk Score for Prediction of Incident Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Development of a Sex-Specific Prevalent Hypertension Discrimination Model in Korean Adults Using Genetic Risk Scores and Clinical Biomarkers: A Cross-Sectional Study.Current issues in molecular biology · 2026Article
- Association Between Vitamin D Deficiency and Cardiometabolic Risk Clustering Among Rural Community-Dwelling Older Adults: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This report provides an overview of hypertension prevalence, management, and trends in South Korea. Methods: The analysis is based on data from Korean adults aged 20 and older, using the 1998-2022 Korea National Health and Nutrition Examination Survey (KNHANES) and the 2002-2022 National Health Insurance (NHI) Big Data. Results: An estimated 30% of Korean adults (13 million) have hypertension, including 7.2 million men, 5.8 million women, and 5.8 million aged 65 or older. Overall awareness, treatment, and control rates were 77%, 74%, and 59%, respectively, showing a tendency to increase with advancing age. Medical utilization for hypertension has steadily increased, with 11.5 million patients accessing medical services, 10.9 million receiving antihypertensive prescriptions, and 8.1 million undergoing continuous treatment in 2022. Prescription patterns reveal monotherapy (40%), dual therapy (44%), and combination therapy with three or more drugs (16%). The most commonly prescribed antihypertensive medications include angiotensin receptor blockers (76%), calcium channel blockers (62%), diuretics (23%), and beta-blockers (15%). Among young adults aged 20-39 with hypertension, 59.2% do not utilize healthcare services, and 84.9% are non-adherent to treatment. Awareness (36%), treatment (35%), and control rates (33%) in this group are notably lower than all age groups of above 40, with treatment continuity rates at 24% for individuals in their 20s and 40% for those in their 30s. Conclusions: While South Korea has achieved relatively high rates of hypertension management compared to many countries, further efforts are needed to reduce hypertension prevalence and improve awareness and treatment adherence, particularly among younger adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.